Funder
Association of Breast Surgery
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447. https://doi.org/10.1056/NEJMoa1600249
2. Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF et al (2015) Impact of neoadjuvant chemotherapy in Stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates. Ann Surg 262:434–439. https://doi.org/10.1097/SLA.0000000000001417
3. Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B et al (2016) Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat 160:297–304. https://doi.org/10.1007/s10549-016-4006-6
4. Franceschini G, Di Leone A, Natale M, Sanchez MA, Masett R (2018) Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. Ann Ital Chir 89:290
5. Dodd GD, Fry K, Delany W (1965) Preoperative localization of occult carcinoma of the breast. In: Nealon TF (ed) Management of the patient with cancer. Saunders, Philadelphia, pp 88–113